AccuLine was founded with the vision to save the lives of millions of people worldwide by preventing the next heart attack. AccuLine is developing CORA – an accurate, non-invasive, swift, and cost-effective examination for early detection of CAD, designed to replace the inaccurate, time-consuming, and labor-intensive stress test examinations. Through a brief 4-minute evaluation of three vital signs - the heart's electrical activity, oxygen saturation levels, and respiratory phase, CORA automatically generates results, ensuring a seamless and efficient process. CORA has the potential to save the lives of millions of patients worldwide, while simultaneously decreasing health care-related costs. AccuLine has received grants from Google and the Israeli Innovation Authority, and among its shareholders are Mayo Clinic, eHealth Ventures and Maccabi Healthcare Services.